

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 306/2017

DESPATCHED ON 13TH JUNE 2017

HLA specificity for assessment		DR1		DR103		DR15		DR16		DR17		DR18		DR4		DR11		DR12		DR13		DR14		DR7		DR8		DR9				
Consensus % reported	Not Assessed	5.7%		2.9%		1.4%		Not Assessed		34.3%		2.9%		4.3%		1.4%		1.4%		2.9%		2.9%		82.9%		1.4%		7.1%				
Lab no.	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI		
9																								DR7	L	< 2000						
11																								DR7	L	< 2000						
12																								DR7	L	< 2000						
14																								DR7	L	< 2000						
15																								DR7	L	< 2000						
19																								DR7	L	< 2000						
20																								DR7	L	< 2000						
23																								DR7	L	< 2000						
24																								DR7	L	< 2000						
25																								DR7	L	< 2000						
26																								DR7	L	< 2000						
28																								DR7	L	< 2000						
34																								DR7	L	< 2000						
35																								DR7	L	< 2000						
38																								DR7	L	< 2000						
39	DR1	C																						DR7	L	< 2000						
41																																
42																								DR7	L	< 2000						
45																																
48																								DR7	L	< 2000						
51																								DR7	L	< 2000						
54																								DR7	L	< 2000						
58																								DR7	L	< 2000						
62																								DR7	L	< 2000						
100																								DR7	L	< 2000						
112																								DR7	L	< 2000						
114																								DR7	L	< 2000						
116																								DR7	L	< 2000						
117																								DR7	L	< 2000						
119																								DR7	L	< 2000						
120																								DR7	L	< 2000						
133																								DR7	L	< 2000						
136																								DR7	L	< 2000						
142																								DR7	L	< 2000						
143																								DR7	L	< 2000						
145																								DR7	L	< 2000						
147																								DR7	L	< 2000						
149																								DR7	L	< 2000						
157																								DR7	L	< 2000						
160																								DR7	L	< 2000						
162																								DR7	L	< 2000						
164																								DR7	L	< 2000						
165																																
169																								DR7	L	< 2000						
181																								DR7	L	< 2000						
185																								DR7	L	< 2000						
195																								DR7	L	< 2000						
197	DR1	L		2000-5000	DR103	L		2000-5000																DR7	L	< 2000						
204																								DR7	L	< 2000						
206																								DR7	L	< 2000						
209																								DR7	L	< 2000						
214																								DR7	L	< 2000						
216																								DR7	L	< 2000						
218																								DR7	L	< 2000						
222	DR1	F		DR103	F		DR15	F		DR16	F		DR17	F		DR18	F		DR4	F		DR11	F		DR12	F		DR13	F		DR14	F
227																								DR7	L	< 2000						
229																								DR7	L	< 2000						
232																																
239																								DR7	L	< 2000						
242																								DR7	L	< 2000						
252																																
267																																
268																																
273																																
277																								DR7	L	< 2000						
284																								DR7	L	< 2000						
293																								DR7	L	< 2000						
302																								DR7	L	< 2000						
303																								DR7	L	< 2000						
309	DR1	L		< 2000																				DR7	L	< 2000						
351																								DR7	L	< 2000						
361																								DR7	L	< 2000						

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	4	< 2000	2	< 2000	1	< 2000	4	< 2000	24	< 2000	2	< 2000	3	< 2000	1	< 2000	1	< 2000	2	< 2000	2	< 2000	58	< 2000	1	< 2000	5	< 2000
Total Participants	70	0	70	0	70	0	70	0	70	0	70	0	70	0	70	0	70	0	70	0	70	0	70	0	70	0	70	0
	1	2000-5000	0	2000-5000	0	2000-5000	1	2000-5000	4	2000-5000	1	2000-5000	0	2000-5000	0	2000-5000	0	2000-5000	0	2000-5000	0	2000-5000	18	2000-5000	0	2000-5000	1	2000-5000
	1	> 5000	0	> 5000	0	> 5000	0	> 5000																				

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 306/2017

DESPATCHED ON 13TH JUNE 2017

HLA specificity for assessment																																	
Consensus % reported	DR10 Not Assessed 27.1%			DR51 Absent 2.9%			DR52 Not Assessed 8.6%			DR53 Present 78.6%			DQ5 Present 81.4%			DQ6 Not Assessed 8.6%			DQ2 Present 98.6%			DQ7 Present 98.6%			DQ8 Present 98.6%			DQ9 Present 98.6%			DQ4 Present 97.1%		
Lab no.	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI			
9																																	
11																																	
12																																	
14																																	
15																																	
19																																	
20																																	
23																																	
24																																	
25																																	
26																																	
28																																	
34																																	
35																																	
38																																	
39																																	
41																																	
42																																	
45																																	
48																																	
51																																	
54																																	
58																																	
62																																	
100																																	
112																																	
114																																	
116																																	
117																																	
119																																	
120																																	
133																																	
136																																	
142																																	
143																																	
145																																	
147																																	
149																																	
157																																	
160																																	
162																																	
164																																	
165																																	
181																																	
189																																	
185																																	
195																																	
197																																	
204																																	
206																																	
209																																	
214																																	
218																																	
222																																	
227																																	
229																																	
232																																	
239																																	
242																																	
252																																	
267																																	
268																																	
273																																	
277																																	
284																																	
293																																	
302																																	
303																																	
309																																	
351																																	
361																																	

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Lumines; O = Other

No. Reporting Spec	19	< 2000	2	< 2000	6	< 2000	55	< 2000	57	< 2000	6	< 2000	69	< 2000	69	< 2000	69	< 2000	69	< 2000	68	< 2000
Total Participants	70	18	70	0	70	3	70	36	70	4	70	4	70	0	70	5	70	13	70	8	70	5
		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000
		0		1		2		17		37		1		4		14		22		27		33
		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000
		0		0		0		1		13		0		64		49		33		33		29

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 306/2017

DESPATCHED ON 13TH JUNE 2017

DPA1* Antibodies - NOT ASSESSED																		
01:03			01:05			02:01			02:02			03:01			04:01			
% reported																		
Lab no.	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI
9							02:01 L		> 500	02:02 L		> 5000			04:01 L			> 500
11							02:01 L		> 500	02:02 L		> 5000			04:01 L			2000+
12																		
14							02:01 L		> 500	02:02 L		> 5000			04:01 L			2000+
15							02:01 L		> 5000						04:01 L			2000+
19							02:01 L		> 5000						04:01 L			2000+
20							02:01 L		> 5000						04:01 L			> 500
23																		
24							02:01 L		> 5000						04:01 L			2000+
25							02:01 L		> 500	02:02 L		> 5000			04:01 L			2000+
26							02:01 L		2000-5000						04:01 L			< 200
28																		
34							02:01 L		2000-5000						04:01 L			2000+
35	01:03 L		> 5000	01:05 L		> 5000	02:01 L		2000-	02:02 L		> 500	03:01 L		> 500	04:01 L		2000+
38							02:01 L		2000-	02:02 L		> 500	03:01 L		> 500	04:01 L		2000+
39							02:01 L		> 5000						04:01 L			2000+
41																		
42							02:01 L		> 500	02:02 L		> 5000			04:01 L			< 200
45							02:01 L		> 500	02:02 L		> 5000			04:01 L			2000+
48							02:01 L		> 500	02:02 L		> 5000			04:01 L			> 500
51							02:01 L		> 500	02:02 L		> 5000			04:01 L			2000+
54							02:01 L		> 5000						04:01 L			2000+
58																		
62																		
100	01:03 L		2000-5000				02:01 L		2000-	02:02 L		2000-	03:01 L		2000-	04:01 L		2000+
112							02:01 L		2000-	02:02 L		2000-5000			04:01 L			2000+
114							02:01 L		> 500	02:02 L		> 500	03:01 L		2000-	04:01 L		2000+
116							02:01 L		> 5000						04:01 L			2000+
117							02:01 L		2000-5000						04:01 L			2000+
119							02:01 L		> 5000						04:01 L			> 500
120							02:01 L		> 5000						04:01 L			2000+
133							02:01 L		> 500	02:02 L		> 5000						
136							02:01 L		> 500	02:02 L		> 500	03:01 L		> 500	04:01 L		2000+
142																		
143																		
145																		
147							02:01 L		> 5000						04:01 L			2000+
149							02:01 L		> 500	02:02 L		> 5000			04:01 L			2000+
157							02:01 L		> 5000						04:01 L			> 500
160							02:01 L		> 500	02:02 L		> 500	03:01 L		2000-	04:01 L		2000+
162							02:01 L		> 5000						04:01 L			2000+
164							02:01 L		> 500	02:02 L		> 5000			04:01 L			> 500
165																		
169																		
181																		
185							02:01 L		2000-	02:02 L		2000-5000			04:01 L			< 200
195																		
197																		
204							02:01 L		> 5000						04:01 L			> 500
206																		
209																		
214							02:01 L		2000-	02:02 L		2000-5000			04:01 L			2000+
216																		
218							02:01 L		2000-	02:02 L		2000-5000			04:01 L			2000+
222																		
227							02:01 L		> 500	02:02 L		> 5000			04:01 L			> 500
229																		
232	01:03 L		2000-5000	01:05 L		2000-5000	02:01 L		> 500	02:02 L		> 500	03:01 L		2000-	04:01 L		2000+
239																		
242																		
252																		
267							02:01 L		2000-	02:02 L		2000-5000			04:01 L			< 200
268																		
273							02:01 L		> 500	02:02 L		> 500	03:01 L		> 500	04:01 L		2000+
277							02:01 L		> 500	02:02 L		> 500	03:01 L		2000-	04:01 L		2000+
284							02:01 L		> 5000						04:01 L			2000+
293																		
302																		
303							02:01 L		> 500	02:02 L		> 500	03:01 L		> 500	04:01 L		2000+
309																		
351	01:03 L		> 5000	01:05 L		> 5000	02:01 L		> 500	02:02 L		> 500	03:01 L		> 500	04:01 L		2000+
361	01:03 L		2000-5000				02:01 L		2000-	02:02 L		2000-5000			04:01 L			2000+

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	5	< 2000	3	< 2000	45	< 2000	28	< 2000	10	< 2000	44	< 2000
	0	0	0	0	0	0	0	0	0	0	4	4
	3	2000-5000	1	2000-5000	10	2000-5000	7	2000-5000	5	2000-5000	32	2000-5000
	2	> 5000	2	> 5000	35	> 5000	21	> 5000	5	> 5000	8	> 5000

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 306/2017

DESPATCHED ON 13TH JUNE 2017

Lab no.	Techniques used IgG	Sample Treatment IgG	High Background	Neg control serum batch	Allele Specific Antibodies IgG	Luminex kit (lot)		Cut-off value	Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot)	Cut-off value	Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot)	Cut-off value	Control bead MFI Positive	Control bead MFI Negative
						IgG	IgG											
9 L		EDTA	N			LS2A01	1000	7000	30									
11 L		EDTA	N	NC17		LS2A01	500	5668	22		LSM12	2.5	5329	34				
12 L		EDTA	N	LOT17	DRB4*01:03	LS2A01	500	9791	36		LSM12	3	13157	66				
14 L		Heat/EDTA	N	17		LS2A01	1500	13004	33									
15 L		EDTA	N	17		LS2A01	1000	8466	63									
19 L		N	N			LS2A01	1000	8043	41									
20 L		EDTA	N		DPB1*18:01? DPB1*28:01?	LS2A01	2000	9613	56									
23 L		EDTA	N		DRB4*01:03	LS2A01	1000	9961	22.36									
24 L		EDTA	N	17		LS2A01	1000	11029	50		LSM12	4.5	9817	30	LS2PRA	1000	9472	37
25		EDTA	N	016	Likely reactivity against DQA (61FT epitope - DQA1*02:01/03:01/03:02/03:03/04:01/05:01/05:03/05:05/06:01)	LS2A01	1000	10038	32		LSM12	6.1	4191	61	LSAII	1500	17528	373
26 L		EDTA	N	017	DOB1*05:01													
28 L		N	N	17	DRB1*16:01 DPB1*18:01 DPA1*02:01 DPB1*28:01 DPA1*04:01	LS2A01	500	7755	29									
34 L		EDTA	N	016		LS2A01	1000	9599	24									
35 L		EDTA	N	017		LS2A01	1000	11135	19									
38			N	LS-NC015	DOB1*05:01 Unable to exclude presence of: DP9/14/15/17 DPA1*02:02/03:01 DQA1*02:01 DQA1*03:01/02/03 DQA1*04:01 DQA1*05:01/03/05 DQA1*06:01	LS2A01	1100	9558	21		LS2PRA		16725	96				
41 L		None	N			LS2A01	2000	7938	28									
42 L		EDTA	N	017		LS2A01	500	6464	23									
45 L		Beads	N		DOB1*05:01	LS2A01	1500	10000	20									
48 L		Heat	N	17														
51		N	N			LS2A01	900	9060	38									
54 L		EDTA	N	016		LS2A01	750	8652	34									
58 L		EDTA	N	016		LS2A01	1000	7523	30		LSM12	3	7196	38				
65 L		None	N		DOB1*05:01	LS2A01	2000	9387	12		LSM12		8259	23.25				
100 L		N	N			LSAII	500	15803	209									
112 L		None	N	110B6D		LSAII	500	22397	364									
114 L		EDTA	N			LS2A01	1000	8092	13									
116 C/L		EDTA	N	17		LS2A01	1000	5847	28		LSM12		8319	36				
117 C/L		None	N	016		LS2A01	500	9387	12									
119		EDTA	N			LS2A01	>1000	6971	25		LSM12	>1.5	6774	18				
120 L		EDTA	N		DRB3*03:01	LS2A01	500	8646	13.08									
133 L		Heat	N	08256C	DOB1*02:01/02:02 DOB1*03:01/03:02/03/03 DOB1*04:01/04:02 DRB1*07:01 DRB4*01:01 DRB1*16:01	LSAII	500	17466	503									
136 L		None	N			LS2A01	1000	8083	38									
142 L		EDTA	N			LS2A01	1000	10139	18									
143 L		None	N	017		LS2A01	1000	10634	43									
145		None	N			LS2A01	500	8130	28									
147 L		None	N		DR1403 and DR1404 NT DOB1*05:01 positive	LS2A01	>1500	13845	15		LSM12	>5	3669	7				
149 L		None	N			LSAII	17283	194										
157		EDTA	N	16	DOB1*06:01	LS2A01	1000	23.88	11330									
160 L		Beads	N	LOT16		LS2A01	900	10800	6.2									
162 L		Beads	Y			LS2A01	1000	11386	33		LSM12	3	7794	19				
164 L		EDTA	N	29		LS2A01	1500	10129	29									
165		None	N			LSAII	17283	194										
169 L		None	N	16		LS2A01	1000	23.88	11330									
181 L		None	N	16		LS2A01	500	9100	15									
185 L		None	N			LSAII	2	17593	152		LM2	0	21143	133				
195 L		None	N			LS2A01	2000	10674	26									
197 L		None	N			LS2A01	1000	8565	15									
204 L		EDTA	N	LSNC		LS2A01	1000	11136	21									
206 L		EDTA	N			LS2A01	1000	11136	21									
209 L		EDTA	N		DR52 = DR3, *03:01 DRB1*09:01 DOB1*06:01	LS2A01	500	15932	97									
214 L		None	N		DOB1*02:01 DOB1*02:02 DOB1*04:01 DOB1*04:02	LSAII	15781	245										
216 L		Heat	N	3005006		LM2	1600	21159	340		LMX		18375					
					DOB1*02:01 DOB1*02:02 DOB1*03:01 DOB1*03:02 DOB1*03:03 DOB1*04:01 DOB1*04:02 DOB1*03:03 DOB1*04:01 DOB1*04:02 DRB1*03:01/DR17 DRB1*07:01 DRB4*01:01/DR53 DQA1*02:01 DQA1*03:01 DQA1*03:02 DQA1*04:01 DQA1*05:01 DQA1*06:01 DPB1*01:01 DPB1*03:01 DPB1*05:01 DPB1*06:01 DPB1*09:01 DPB1*11:01 DPB1*13:01 DPB1*14:01 DPB1*15:01 DPB1*17:01 DPB1*19:01 DPB1*28:01 DPA1*02:01 DPA1*02:02 DPA1*04:01	LSAII	20252											
222 F		None	N															
227 L		DI/EDTA	N															
229		None	N	NC17	DOB1*02:01 DOB1*03:01 DOB1*03:03 DOB1*03:02 DOB1*04:01 DOB1*02 DOB1*05:01	LS2A07	1200	6181	19									
232 L		None	N			LM2	900	17930	92									
239 L		Beads	N			LS2A01	1500	14539	24									
242 L		None	N			LM2	2	10703	109									
252 L		EDTA	N			LSAII	700	12490	140									
267 L		EDTA	N			LSAII	1500	15073	494		LM2	1000	19326	79				
268 C/L		None	N			LS2A01	1500	8139	22									
273 L		None	N	016		LS2A01	500	6019	20									
277 L		EDTA	N			LS2A01	1000	7751	32									
284 L		None	N			LS2A01	500	7421	13.1		LS2PRA	500	7421	13.1				
293 L		None	N			LS2A01	500	7421	13.1									
302 L		None	N			LSAII	17283	194										
305 L		Heat/Beads	Y	017		LS2A01	1000	7577	32									
309 L		None	N			LSAII	900	17000	90									
351 L		EDTA	N	017		LS2A01	1500	13357	17									
361 L		None	N	3004913		LSAII	500	16490	172									

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex O = Other

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 307/2017

DESPATCHED ON 13TH JUNE 2017

DQA1* Antibodies - NOT ASSESSED																													
		02:01		03:01		03:02		03:03		04:01		05:01		05:03		05:05		06:01											
% reported																													
Lab no.	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI		
9																													
11																													
12																													
14																													
15																													
19																													
20																													
23																													
24																													
25																													
26																													
28																													
34																													
35	02:01 L		2000-	03:01 L		2000-	03:02 L		2000-5000					05:03 L	> 500	05:05 L		> 500	06:01 L		> 500								
38																													
39																													
41																													
42																													
45																													
48																													
51																													
54																													
58																													
62																													
100	02:01 L		< 200	03:01 L		< 200	03:02 L		< 2000		04:01 L	< 200	05:01 L	< 2000							06:01 L	< 200							
112																													
114				03:01 L		2000-	03:02 L		2000-5000				05:01 L	< 200	05:03 L	> 500	05:05 L		> 500	06:01 L		> 500							
116																													
117																													
119																													
120																													
133																													
136				03:01 L		> 500	03:02 L		> 5000					05:03 L	> 500	05:05 L		> 500	06:01 L		> 500								
142																													
143																													
145																													
147																													
149																													
157																													
160				03:01 L		2000-	03:02 L		2000-5000					05:03 L	> 500	05:05 L		> 500	06:01 L		> 500								
162																													
164															05:03 L	> 500	05:05 L		> 500	06:01 L		> 500							
165																													
169																													
181																													
185																													
195																													
197																													
204																													
206																													
209																													
214																													
216																													
218																													
222																													
227																													
229																													
232	02:01 L		2000-	03:01 L		2000-	03:02 L		2000-5000					05:03 L	2000-	05:05 L		> 500	06:01 L		> 500					2000-			
239																													
242																													
252																													
267																													
268																													
273				03:01 L		2000-	03:02 L		> 5000					05:03 L	> 500	05:05 L		> 500	06:01 L		> 500								
277							03:02 L		> 5000					05:03 L	> 500	05:05 L		> 500	06:01 L		> 500								
284																													
293																													
302																													
303							03:02 L		> 5000						05:03 L	> 500	05:05 L		> 500	06:01 L		> 500							
309	02:01 L		> 500 C	L		< 200	03:02 L		< 200	03:03 L		< 200	04:01 L	< 200	05:01 L	< 200		05:03 L	> 500	05:05 L		> 500	06:01 L		> 500				
351	02:01 L		> 500	03:01 L		> 500	03:02 L		> 5000						05:03 L	> 500	05:05 L		> 500	06:01 L		> 500							
361																													

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	5	< 2000	8	< 2000	11	< 2000	1	< 2000	2	< 2000	3	< 2000	11	< 2000	11	< 2000	12	< 2000
	1	2000-5000	2	2000-5000	2	2000-5000	0	2000-5000	2	2000-5000	3	2000-5000	1	2000-5000	1	2000-5000	2	2000-5000
	1		4		4		0		0		0		1		0		1	
		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000
	3		3		5		0		0		0		9		10		9	

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 307/2017

DESPATCHED ON 13TH JUNE 2017

DPB1* Antibodies - NOT ASSESSED

Lab no.	01:01		03:01		04:01		04:02		05:01		06:01		11:01		13:01		14:01		15:01		17:01		19:01		23:01				
	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech
9																													
11																													
12																													
14																													
15																													
19																													
20																													
23																													
24																													
25																													
26																													
28														11:01 L	<2000													23:01 L	
34																													
35																													
38																													
39																													
41																													
42																													
45																													
48																													
51																													
54														11:01 L	<2000														
58																													
62																													
100																													
112																													
114																													
116																													
117																													
119																													
120																													
133																													
136														11:01 L	<2000														
142														11:01 L	<2000														
143																													
145																													
147																													
149																													
157																													
160																													
162																													
164																													
165																													
169																													
181														11:01 L	<2000														
185																													
195																													
197																													
204																													
206																													
209														11:01 L	<2000														
214																													
216																													
218																													
222																													
227																													
229																													
232																													
239																													
242																													
252																													
267																													
268																													
273																													
277																													
284																													
293																													
302																													
303																													
309	01:01 L	> 5000	03:01 L	> 5000	04:01 L	> 500	04:02 L	> 500	05:01 L	> 500	06:01 L	> 500	11:01 L	> 500	13:01 L	> 500	14:01 L	> 500	15:01 L	> 500	17:01 L	> 500	19:01 L	> 500					
351													11:01 L	<2000															
361																													

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	1	< 2000	1	< 2000	1	< 2000	1	< 2000	1	< 2000	8	< 2000	1	< 2000	1	< 2000	1	< 2000	1	< 2000	1	< 2000	1	< 2000	1	< 2000	2	< 2000
	0	0	0	0	0	0	0	0	0	0	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 307/2017

DESPATCHED ON 13TH JUNE 2017

DPA1* Antibodies - NOT ASSESSED									
02:01			02:02			04:01			
% reported									
Lab no.	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI
9									
11									
12									
14									
15									
19									
20									
23									
24									
25									
26									
28									
34									
35									
38									
39									
41									
42									
45									
48									
51									
54									
58									
62									
100									
112									
114									
116									
117									
119									
120									
133									
136									
142									
143									
145									
147									
149									
157									
160									
162									
164									
165									
169									
181									
185									
195									
197									
204									
206									
209									
214									
216									
218									
222									
227									
229									
232									
239									
242									
252									
267									
268									
273									
277									
284									
293									
302									
303									
309	02:01 L		> 500	02:02 L		> 500	04:01 L		> 5000
351				02:02 L		< 2000			
361									

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	1	< 2000	2	< 2000	1	< 2000
	0		1		0	
	0	2000-5000	0	2000-5000	0	2000-5000
	0		0		0	
	0	> 5000	0	> 5000	0	> 5000
	1		1		1	

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 307/2017

DESPATCHED ON 13TH JUNE 2017

Techniques used IgG	Sample Treatment IgG	High Background	Neg control serum batch	Allele Specific Antibodies IgG	Luminex kit (lot) IgG	Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot) IgG	Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot) IgG	Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative
9 L	EDTA	N			LS2A01	1000	10200	45								
11 L	EDTA	N	NC17		LS2A01	500	4992	24								
12 L	EDTA	N	LOT 17		LS2A01	500	10522	87	LSM12	2.5	5911	39				
14 L	Heat/EDTA	N	17	DRB1*14:02	LS2A01	1500	15085	48	LSM12	3	10867	189				
15 L	EDTA	N	17	DRB1*14:02 DRB1*09:01	LS2A01	1000	13953	82.1								
19 L	None	N		DRB1*14:02	LS2A01	1000	8968	39								
20 L	EDTA	N		DRB1*01:01	LS2A01	2000	14162	102								
23 L	EDTA	N	17	DRB1*14:02	LS2A01	1000	9524	16.93								
24 L	EDTA	N	17		LS2A01	1000	14745	90	LSM12	4.5	11007	72	LS2PRA	1000	9949	173
25 L	EDTA	N	016	DRB1*14:02	LS2A01	1000	11801	65	LSM12	6.1	12008	259	LSAII	1500	21317	4006
26 L		N	017													
28 L	None	N		DRB1*15:03 DQB1*04:01 DQA1*03:03 DPB1*11:01	LS2A01	500	8086	55								
34		N	016	DRB1*14:02	LS2A01	1255	11874	28								
35 L	EDTA	N	017	DRB1*14:02	LS2A01	1000	10585	22								
38		N			LS2A01	1000	14364	14	LS2PRA		16708	97				
39 L		N	LS-NC015	DRB1*14:02	LS2A01	1200	11341	14								
41 L	None	N			LS2A01	2000	9052	19								
42 L	EDTA	N	17	DRB1*14:02	LS2A01	500	8064	22								
45 L	Beads/EDTA	N			LS2A01	1500	13000	30								
48 L	Heat	N	17													
51	EDTA	N	016	DRB1*14:01 DRB1*14:02	LS2A01	750	9797	74								
58 L	EDTA	N	016		LS2A01	1000	8551	147	LSM12	3	9844	128				
62 L	None	N			LS2A01	1000			LSM12	0	10234	30.18				
100 L		N			LSAII	500	15803	226								
112 L	None	N	110B6D		LSAII	500	22209	410								
114 L	EDTA	N			LS2A01	1000	9335	29								
116 C/L	EDTA	N	17	DRB1*14:02	LS2A01	1000	7573	31	LSM12	10211	83					
117 L	None	N	016		LS2A01	500	11441	25								
119 L	EDTA	N			LS2A01	>1000	9179	28	LSM12	>1.5	8287	28				
120 L	EDTA	N		DRB1*14:01 DRB1*14:02	LS2A01	500	9393.7	13.89								
133 L	Heat/Beads	Y	02856C	DRB1*04:~104:02/04:03/04:05	LSAII	500	15835	24								
136	None	N		DRB1*14:02 DRB1*14:01 DPA1*02:02/DPB1*11:01	LS2A01	1000	10816	50								
				DQA1*03:01/DQB1*03:01 DQA1*03:01/DQB1*03:02												
				DQA1*03:01/DQB1*03:03												
142 L	EDTA	N		DRB1*10:01	LS2A01	1000	9415	24								
143 L	None	N	017		LS2A01	1000	14244	26								
145 L	None	N			LS2A01	1000	9908	32								
147 L	EDTA	N		DRB1*14:02	LS2A01	>1500	11948	465	LSM12	>5	3943	10				
149 L	None	N			LSAII		14766	160								
157 L	EDTA	N	16	DRB1*09:01	LS2A01	1000	16:09	13778								
160 L	Beads	N	16		LS2A01	1000	11400	8.3								
162 L	EDTA	N		DRB1*14:02	LS2A01	1000	9856	23	LSM12	3	1901	30				
164 L	EDTA	N	29		LS2A01	1500	5731	35								
165																
169 L	None	N	IH		LS2A01	1000	20000	60								
181	EDTA	N			LS2A01	500	9100	15								
185 L	None	N			LSAII	2	18460	184	LM2	0	30043	111				
195 L	None	N			LS2A01	2000	11310	26								
197 L	None	N														
204 L	EDTA	N	LSNC		LS2A01	1000	10022	18								
206	EDTA	N		DRB1*14:02	LS2A01	1000	10136	29								
209	Beads/EDTA	N			LS2A01	500	15676	20								
					LSAII		18613	311								
214 L				DRB1*01:01 DRB1*01:02 DRB1*04:01 DRB1*04:02												
216 L	None	N	3005006	DRB1*04:03 DRB1*04:04 DRB1*04:05	LM2	1140	19901	108	LMX		17779					
	Heat				LSAII		20100									
218				DQB1*03:01 DQB1*03:02 DQB1*03:03 DRB1*01:01												
				DRB1*01:02 DRB1*03:01/DR17 DRB1*04:01 DRB1*04:02												
				DRB1*04:03 DRB1*04:04 DRB1*04:05 DRB1*11:01												
222 F	None															
227 L	DII/EDTA	N		14:02												
229	None	N	NC17	DRB1*04:04 DRB1*04:01 DRB1*04:02 DRB1*04:03	LS2A01	1200	8002	69								
				DRB1*04:03 DRB1*01:01 DRB1*01:02 DQB1*03:01												
232				DQB1*03:03 DQB1*03:02												
239 L	None	N			LM2	1000	18394	169								
242 L	Beads	N			LS2A01		17194	22								
252 L	None	N			LM2	2	16304	101								
267 L	EDTA	N			LSAII	700	12310	133								
268 C/L	None	N			LSAII	1500	15775	1334								
273 L	None	N		DRB1*14:02	LS2A01	1500	9061	29	LM2	1000	19296	62				
277 L	EDTA	N	016	DRB1*14:02 DRB1*14:01	LS2A01	500	6526	22								
284 L	EDTA	N			LS2A01	1000	10172	39								
293 L	None	N			LS2A01	500	8239	8.32	LS2PRA	500	8239	8.32				
302 L	None	N	017		LS2A01	1000	8722	38								
303 L	None	N			LSAII	500	17000	100								
351 L	EDTA	N	017		LS2A01	1500	15869	33								
361 L	None	N	3004913	DRB1*01:01	LSAII	500	15391	136								

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 308/2017

DESPATCHED ON 13TH JUNE 2017

HLA specificity for assessment		DR1		DR103		DR16		DR17		DR18		DR4		DR11		DR12		DR13		DR14		DR1403		DR1404		DR8				
Consensus % reported	Not Assessed	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech
	5.7%			<2000			61.4%			70.0%			45.7%		97.1%	48.6%		92.9%		94.3%		8.6%		14.3%		94.3%				
Lab no.	DR1	L			DR16	L	DR17	L	DR18	L	DR4	L	DR11	L	DR12	L	DR13	L	DR14	L	DR1403	L	DR1404	L	DR8	L				
9																														
11																														
12																														
14																														
15																														
19																														
20																														
23																														
24																														
25																														
26																														
28																														
34																														
35																														
38																														
39																														
41																														
42																														
45																														
48																														
51																														
54																														
58																														
62																														
100																														
112																														
114																														
116																														
117																														
119																														
120																														
133																														
136																														
142																														
143																														
145																														
147																														
149																														
157																														
160																														
162																														
164																														
165																														
169	DR1	L		<2000																										
181																														
185																														
195																														
197																														
204																														
206																														
209																														
214																														
216	DR1	L		<2000																										
218																														
222																														
227																														
229																														
232																														
239																														
242																														
252																														
267																														
268																														
273																														
277																														
284																														
293																														
302	DR1	L		2000-5000	DR103	L	<2000																							
303																														
309																														
351																														
361																														

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	4	<2000	1	<2000	43	<2000	49	<2000	43	<2000	32	<2000	68	<2000	34	<2000	65	<2000	66	<2000	6	<2000	10	<2000	66	<2000
Total Participants	70	3	70	1	70	28	70	40	70	35	70	24	70	33	27	70	32	70	26	70	6	70	9	70	21	70
		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000
		1		0		12		7		6		29		4		27		32		6		0		0		39
		>5000		>5000		>5000		>5000		>5000		>5000		>5000		>5000		>5000		>5000		>5000		>5000		>5000
		0		0		2		1		1		1		5		1		4		6		0		1		5

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 308/2017

DESPATCHED ON 13TH JUNE 2017

HLA specificity for assessment																							
Consensus % reported	DR10 Absent 1.4%		DR52 Not Assessed 44.3%		DR53 Absent 1.4%		DQ6 Absent 1.4%		DQ2 Absent 1.4%		DQ7 Absent 4.3%		DQ8 Absent 1.4%		DQ4 Absent 2.9%								
	spec	tech	MFI < 200	spec	tech	MFI spec	tech	MFI spec	tech	MFI spec	tech	MFI spec	tech	MFI spec	tech	MFI spec							
Lab no.																							
9																							
11																							
12																							
14																							
15																							
19																							
20																							
23																							
24																							
25																							
26																							
28																							
34																							
35																							
38																							
39																							
41																							
42																							
45																							
48																							
51																							
54																							
58																							
62																							
100																							
112																							
114																							
116																							
117																							
119																							
120																							
133																							
136																							
142																							
143																							
145																							
147																							
149																							
157																							
160																							
162																							
164																							
165																							
169																							
181																							
185																							
195																							
197																							
204																							
206																							
209																							
214																							
216																							
218																							
222																							
227																							
229																							
232																							
239																							
242																							
252																							
267																							
268																							
273																							
277																							
284																							
293																							
302																							
303																							
309																							
351																							
361																							

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	1	< 2000	31	< 2000	1	< 2000	1	< 2000	1	< 2000	3	< 2000	1	< 2000	2	< 2000
Total Participants	70	1	70	28	70	0	70	1	70	1	70	2	70	0	70	1
		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000
	0		0		1		0		0		0		1		0	
	> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000	
	0		0		0		0		0		0		0		0	

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 308/2017

DESPATCHED ON 13TH JUNE 2017

DQA1* Antibodies - NOT ASSESSED

% reported

Lab no.
9
11
12
14
15
19
20
23
24
25
26
28
34
35
38
39
41
42
45
48
51
54
58
62
100
112
114
116
117
119
120
133
136
142
143
145
147
149
157
160
162
164
165
169
181
185
195
197
204
206
209
214
216
218
222
227
229
232
239
242
252
267
268
273
277
284
293
302
303
309
351
361

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Ot

No. Reporting Spec

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 308/2017

DESPATCHED ON 13TH JUNE 2017

DPB1* Antibodies - NOT ASSESSED											
01:01			09:01			19:01					
% reported											
Lab no.	spec	tech	MFI	spec	tech	MFI	MFI	spec	tech	MFI	
9											
11											
12				09:01 L		<2000					
14											
15											
19											
20				09:01 L		<2000					
23											
24											
25											
26											
28								19:01 L		<2000	
34											
35											
38											
39											
41											
42											
45											
48											
51											
54											
58											
62											
100											
112											
114											
116											
117								19:01 E/L		<2000	
119											
120											
133								19:01 L		<2000	
136											
142											
143											
145											
147	01:01 L		<2000					19:01 L		2000-	
149											
157											
160											
162											
164											
165											
169											
181											
185											
195											
197											
204											
206											
209											
214											
216											
218											
222											
227											
229											
232											
239											
242											
252											
267											
268											
273											
277								19:01 L		<2000	
284											
293											
302											
303											
309											
351											
361											

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	1	<2000	2	<2000	5	<2000
	1		2		4	
	2000-5000		2000-5000		2000-5000	
	0		0		1	
	>5000		>5000		>5000	
	0		0		0	

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 308/2017

DESPATCHED ON 13TH JUNE 2017

DPA1* Antibodies - NOT ASSESSED

% reported

Lab no.
9
11
12
14
15
19
20
23
24
25
26
28
34
35
38
39
41
42
45
48
51
54
58
62
100
112
114
116
117
119
120
133
136
142
143
145
147
149
157
160
162
164
165
169
181
185
195
197
204
206
209
214
216
218
222
227
229
232
239
242
252
267
268
273
277
284
293
302
303
309
351
361

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = O

No. Reporting Spec

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 308/2017

DESPATCHED ON 13TH JUNE 2017

Techniques used IgG	Sample Treatment IgG	High Background	Neg control serum batch	Allele Specific Antibodies IgG	Luminex kit (lot) IgG	Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot) IgG	Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot) IgG	Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative
9 L	EDTA	N			LS2A01	500	7600	60								
11 L	EDTA	N	NC17		LS2A01	500	2751	27	LSM12	2.5	3377	34				
12 L	EDTA	N	LOT 17		LS2A01	500	7374	45	LSM12	3	9978	102				
14 L	Heat/EDTA	N		DRB1*14:01 DRB1*14:54 DRB1*04:04												
15 L	EDTA	N	17	DRB1*14:01 DRB1*14:54 13:03 16:02	LS2A01	1000	7343.15	133.66								
19 L	N	N		DRB1*16:02 DRB1*14:54 DRB1*14:01	LS2A01	1000	8157	101								
20 L	Beads/EDTA	N		DRB1*14:01 DRB1*14:54 DRB1*13:03 DRB1*16:02	LS2A01	2000	9745	22								
23 L	EDTA	N	17	DRB1*04:01 DRB1*04:04 DRB1*16:02 DRB3*03:01	LS2A01	1000	8730	25.12								
24 L	EDTA	N	017		LS2A01	1000	8637	44	LSM12	4.5	8246	36	LS2PRA	1000	9364	29
25 L	EDTA	N	016		LS2A01	1000	10164	26	LSM12	6.1	9718	110				
26 L	EDTA	N	017	DRB1*13:03												
28 L	N	N	17	DRB1*04:01 DRB1*04:02 DRB1*04:04 DRB3*03:01	LS2A01	500	7945	47								
34 L	EDTA	N	016	DRB1*14:01 DRB1*14:54 DRB1*16:02	LS2A01	1000	9580	49								
35 L	EDTA	N	017	DRB1*14:01 DRB1*14:54 DRB1*13:03	LS2A01	1000	8273	19								
38				DRB3*03	LS2A01	1000	12762	13								
39 L	N	N	LS-NC015	DRB1*13:03 DRB1*14:01 DRB1*14:54	LS2A01	1500	8418	34	LS2PRA		16115	113				
41 L	None	N			LS2A01	2000	7933	32								
42 L	EDTA	N	017	DRB1*04:01 DRB1*04:04 DRB1*12:01 DRB3*03:01	LS2A01	500	6175	28								
45 L	Beads/EDTA	N			LS2A01	1500	10000	70								
46 L	Heat	N	17													
51 L	N	N		DRB3*03:01	LS2A01	400	8653	102								
54 L	EDTA	Y	016	DRB1*04:04	LS2A01	750	8148	1119								
58 L	EDTA	N	016	DRB1*04:04	LS2A01	1000	6480	39	LSM12	3	7577	51				
62 L	None	N			LS2A01	1500	8021	52.49	LSM12	1						
100 L	None	N			LSAII	500	16307	187								
112 L	None	N	110B6D		LSAII	500	22945	437								
114 L	EDTA	N		DRB1*04:04	LS2A01	1000	8274	18								
116 C/L	EDTA	N	17		LS2A01	1000	5970	34	LSM12		8096	205				
117 L	None	N	016		LS2A01	500	10019	18								
119	EDTA	N	016		LS2A01	>1000	8155	25	LSM12	>1.5	9335	34				
120 L	EDTA	N		DRB1*04:01 DRB1*04:02 DRB1*03:01 DRB3*02:02	LS2A01	500	8184.5	14.24								
133	Heat	N	08256C	DRB1*03:01/03:02/03:03 DRB1*08:01	LSAII	500	17598	357								
L				DRB1*11:01/11:04 DRB1*13:01/13:03												
136 L	None	Y		DRB1*14:01/14:04 DRB3*03:01 DRB1*04:01 DRB1*04:02 DRB1*04:03	LS2A01	1000	9239	76								
142 L	None	N		DRB1*08:01 DRB1*03:01 DRB1*03:02	LS2A01	1000	9908	22								
143 L	None	N	017		LS2A01	1000	10570	30								
145 L	None	N		DRB1*04:04 DRB3*03:01	LS2A01	1000	7182	50								
L	EDTA	N		DRB1*04:01 DRB1*04:03 DRB1*04:04 DRB3*02:02	LS2A01	>1500	19478	24	LSM12	>5	3884	8				
147				DRB3*03:01 DRB1*13:01/13:03 (13:02 NT) DQ7 and DP1 A partially recognised, DR1403 and DR1414 NT												
149 L	None	N			LSAII		15420	261								
157 L	EDTA	N	16	DRB1*16:02 DRB1*04:04	LS2A01	1000	24.43	11066								
160					LS2A01	1000	9200	8.6								
162 L	EDTA	N		DRB1*14:01 DRB1*14:54	LS2A01	1000	7041	23	LSM12	3	7816	22				
164 L	EDTA	N	29	DRB3*03:01 DRB1*04:01 DRB1*04:04	LS2A01	1500	7661	50								
165																
169 L	None	N	IH		LS2A01	1000	12200	53								
181 L	None	N			LS2A01	500	9100	15								
185 L	None	N			LSAII	2	18205	157	LM2	0	19942	162				
195 L	None	N			LSA01	2000	9480	30								
197 L	None	N														
204 L	EDTA	N	LSNC	DRB1*04:01 DRB1*04:04 DRB3*02:02 DRB3*03:01	LS2A01	1000	10687	21								
206 L	EDTA	N		DRB1*04:04	LS2A01	1000	9339	21								
209					LS2A01	500	12669	12								
214				DRB1*08:01 DRB1*08:02 DRB1*11:01 DRB1*11:03	LSAII&I		19038	301								
L				DRB1*11:04 DRB1*13:01 DRB1*13:03												
216 L	None	N	3005006		LM2	1100	19163	123	LMX		19158					
218	Heat	N		DRB1*08:01 DRB1*08:02 DRB1*11:01 DRB1*11:03	LSAII		18961									
L				DRB1*11:04 DRB1*13:03 DRB1*14:01 DRB1*14:04												
222 F	None	N		DRB1*03:01/DR17 DRB1*12:01 DRB1*03:03/DR18												
227 L	None	N		DRB1*13:05 DRB1*14:03 DRB1*13:01												
229	DI/EDTA	N		DRB1*13:02/DR18												
232				DRB3*03:01												
239 L	None	N	NC17	DRB1*14:01 DRB1*08:01 DRB1*11:04 DRB1*13:03	LS2A01	1200	5122	31								
242 L	None	N		DRB1*11:01 DRB1*14:54												
252 L	Beads	N			LM2	900	17427	135								
267 L	EDTA	N			LS2A01	2	13415	25								
269 C/L	None	N			LM2	700	16234	157								
273 L	None	N		DRB1*13:03 DRB1*14:01/14:54 DRB1*16:01	LSAII	1500	12424	128	LM2	1000	18250	76				
277	EDTA	N	016	DRB3*03:01 DRB1*04:04 DRB1*04:01 DRB1*04:03	LS2A01	1500	7238	35								
L					LS2A01	500	5716	27								
284 L	EDTA	N		DRB1*04:04	LS2A01	1000	8644	28								
293 L	None	N			LS2A01	500	7127	8.56	LS2PRA	500	7127	8.56				
302 L	None	N														
303 L	Heat/EDTA	Y	017		LS2A01	1000	6664	93								
309 L	None	N			LSAII	500	17000	60								
351 L	EDTA	N	017		LS2A01	1500	12045	15								
361 L	None	N	3004913	DRB1*13:03	LSAII	500	16472	140								

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 309/2017

DESPATCHED ON 13TH JUNE 2017

HLA specificity for assessment													
Consensus % reported	DR15 Absent 1.4%		DR4 Not Assessed 5.7%			DR53 Not Assessed 10.0%			DQ6 Absent 1.4%		DQ2 Absent 4.3%		
	spec	tech	MFI	spec	tech	MFI	MFI	spec	tech	MFI	spec	tech	MFI
Lab no.													
9													
11													
12													
14													
15													
19													
20													
23													
24													
25													
26													
28													
34													
35													
38								DR53	L				< 2000
39								DR53	L				< 2000
41													
42													
45													
48													
51								DR53	L				< 2000
54													
58													
62													
100													
112													
114													
116													
117													
119													
120													
133													
136													
142													
143								DR4	L				< 2000
145													
147								DR4	L				< 2000
149													
157													
160													
162													
164													
165													
169													
181													
185													
195													
197													
204													
206													
209													
214													
216													
218													
222													
227													
229										DQ6	F		
232													
239													
242													
252													
267													
268													
273													
277													
284								DR53	L				< 2000
293													
302													
303													
309													
351													
361													

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	1	< 2000	4	< 2000	7	< 2000	1	< 2000	3	< 2000
Total Participants	70	1	70	4	70	7	70	0	70	3
		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000
		0		0		0		0		0
		> 5000		> 5000		> 5000		> 5000		> 5000
		0		0		0		0		0

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 309/2017

DESPATCHED ON 13TH JUNE 2017

DQA1* Antibodies - NOT ASSESSED

% reported

Lab no.
9
11
12
14
15
19
20
23
24
25
26
28
34
35
38
39
41
42
45
48
51
54
58
62
100
112
114
116
117
119
120
133
136
142
143
145
147
149
157
160
162
164
165
169
181
185
195
197
204
206
209
214
216
218
222
227
229
232
239
242
252
267
268
273
277
284
293
302
303
309
351
361

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Oth

No. Reporting Spec

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 309/2017

DESPATCHED ON 13TH JUNE 2017

DPB1* Antibodies - NOT ASSESSED																
	01:01			10:01			14:01			23:01			28:01			
% reported	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	
Lab no.																
9																
11																
12																
14																
15																
19																
20																
23																
24																
25																
26																
28																
34																
35																
38																
39																
41																
42																
45																
48																
51																
54																
58																
62																
100																
112																
114																
116																
117																
119																
120																
133																
136							14:01 L		< 200	23:01 L		< 2000				
142																
143																
145																
147	01:01 L		< 2000	10:01 L		< 2000										
149																
157																
160																
162																
164																
165																
169																
181																
185																
195																
197																
204																
206																
209													28:01:00 L	< 2000		
214																
216																
218																
222																
227																
229																
232																
239																
242																
252																
267																
268																
273																
277																
284																
293																
302																
303																
309																
351																
361																

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	1	< 2000	1	< 2000	1	< 2000	1	< 2000	1	< 2000
		1		1		1		1		1
		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000
		0		0		0		0		0
		> 5000		> 5000		> 5000		> 5000		> 5000
		0		0		0		0		0

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 309/2017

DESPATCHED ON 13TH JUNE 2017

DPA1* Antibodies - NOT ASSESSED
04:01

% reported			
Lab no.	spec	tech	MFI
9			
11			
12			
14			
15			
19			
20			
23			
24			
25			
26			
28			
34			
35			
38			
39			
41			
42			
45			
48			
51			
54			
58			
62			
100			
112			
114			
116			
117			
119			
120			
133			
136			
142			
143			
145			
147	04:01 L		< 2000
149			
157			
160			
162			
164			
165			
169			
181			
185			
195			
197			
204			
206			
209			
214			
216			
218			
222			
227			
229			
232			
239			
242			
252			
267			
268			
273			
277			
284			
293			
302			
303			
309			
351			
361			

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Ot

No. Reporting Spec	1	< 2000
	1	
		2000-5000
		0
		> 5000
		0

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 309/2017

DESPATCHED ON 13TH JUNE 2017

Techniques used IgG	Sample Treatment IgG	High Background	Neg control serum batch	Allele Specific Antibodies		Luminex kit (lot)		Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot)		Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot)	Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative		
				IgG	IgG	IgG	IgG														
Lab no.																					
9 L	EDTA	N				LS2A01	500	10100	43												
11 L	None	N	NC17			LSM12	2.5	4840	28												
12 L	EDTA	N	LOT 17			LSM12	500	7221	55		LSM12	3	16049	301							
14 L	Heat/EDTA	N	17			LS2A01	1500	15769	39												
15 L	EDTA	N	17		Class II Negative	LS2A01	1000	13155	99.8												
19 L	None	N				LS2A01	1000	9370	49												
20 L	EDTA	N				LS2A01	2000	11107	201												
23 L	EDTA	N	17			LS2A01	1000	9534	11.63												
24 L	EDTA	N	17			LSM12	4.5	12370	175		LS2PRA	1000	12032	580							
25 L	EDTA	Y	016			LS2A01	1000	10962	55		LSM12	6.1	15024	122							
26 L	EDTA	N	017																		
28 L	None	N	17			LS2A01	500	10220	43												
34 L	EDTA	N	016			LS2A01	1000	10152	24												
35 L	EDTA	N				LS2A01	1000	10057	6												
38					Weak DR53	LS2A01	1000	15978	11		LS2PRA		16643	85							
39 L		N	LS-NC015			LS2A01	1000	9287	21												
41 L	None	N				LS2A01	2000	9286	15												
42 L	EDTA	N	017			LS2A01	500	9431	25												
45 L	Beads/EDTA	N				LS2A01	1500	15000	90												
48 L	Heat	N	17																		
51 L		N				LS2A01	900	10246	44												
54 L	EDTA	N	016			LS2A01	750	9495	127												
58 L	EDTA	N	016			LS2A01	1000	11226	131		LSM12	3	14556	378							
62 L	None	N				LS2A01	2000	11831	29.62												
100 L		N				LSAII	500	15232	154												
112 L	None	N	110B6D			LSAII	500	22616	304												
114 L	EDTA	N				LS2A01	1000	8937	10												
116 C/L	EDTA	N	17			LS2A01	1000	9243	33		LSM12		1032	94							
117 E/L	None	N	016			LS2A01	500	12740	26												
119						LS2A01	>1000	8926	21		LSM12	>1.5	8424	36							
120 L	EDTA	N				LS2A01	500	10400	8.61												
133 L	Heat	N	08256C			LSAII	500	17370	235												
136 L	None	N				LS2A01	1000	13551	104												
142 L	EDTA	N				LS2A01	1000	11486	22												
143 L	None	N	017			LS2A01	1000	12899	20												
145																					
147 L	EDTA	N			DRB1*04:04 DR1403 and DR1404 NT	LS2A01	>1500	24275	29		LSM12	>5	4772	21							
149 L	None	N				LSAII		13914	178												
157		N				LS2A01	1000	15.65	10996												
160 L	Beads	N	LOT16			LS2A01	1000	12160	7												
162 L	EDTA	N				LSM12	3	8694	22												
164 L	EDTA	N	29		All beads are <1000 and considered negative	LS2A01	1500	9962	33												
165																					
169 L	None	N	IH			LS2A01	1000	5000	19												
181 L	None	N	16			LS2A01	500	12900	17												
185 L	EDTA	N				LSAII	2	18081	171		LM2	0	19183	54							
195 L	None	N				LS2A01	2000	12965	31												
197 L	None	N																			
204 L	EDTA	N	LSNC			LS2A01	1000	11699	16												
206 L	EDTA	N				LS2A01	1000	13668	30												
209 L	Beads/EDTA	N				LS2A01	500	15641	15												
214																					
216 L	None	N	3005006			LM2	1000	19668	138		LMX		16670								
218 L	Heat	N				LSAII		19882													
222 F	None	N																			
227	Dii/EDTA	N																			
229																					
232 L	None	N	NC17			LS2A01	1200	9577	55												
239 L	None	N				LM2	2000	18989	292												
242 L	Beads	N				LS2A01		16142	21												
252 L	None	N				LM2	2	15716	101												
267 L	EDTA	N				LSAII	700	12051	152												
268 C/L	None	N				LSAII	1500	14973	236		LM2	1000	18963	61							
273 L	None	N				LS2A01	1500	11921	41												
277 L	EDTA	N	016			LS2A01	500	6778	18												
284 L	EDTA	N				LS2A01	1000	10381	30												
293 L	None	N				LS2A01	500	7906	11.14		LS2PRA	500	7906	11.14							
302 L	None	N																			
303 L	EDTA	N	017			LS2A01	7955	27													
309 L	None	N				LSAII	500	17000	120												
351 L	EDTA	N	017			LS2A01	1500	16532	14												
361 L	None	N	3004913			LSAII	500	17099	175												

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 310/2017

DESPATCHED ON 13TH JUNE 2017

DQA1* Antibodies - NOT ASSESSED																
	01:01		01:02		01:03		01:04		05:05							
% reported	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	
Lab no.																
9																
11																
12																
14																
15																
19																
20																
23																
24																
25																
26																
28																
34																
35																
38																
39																
41																
42																
45																
48																
51																
54																
58																
62																
100	01:01 L		< 2000	01:02 L		< 200	01:03 L		< 2000	01:04 L		< 2000				
112	01:01 L		< 2000													
114																
116																
117																
119																
120																
133	01:01 L		< 2000							01:04 L		< 2000				
136																
142																
143																
145																
147													05:05 L		< 2000	
149	01:01 L		< 2000													
157																
160																
162																
164																
165																
169																
181																
185	01:01 L		< 2000				01:03 L		< 2000							
195																
197																
204																
206																
209																
214																
216																
218	01:01 L		< 2000	01:02 L		< 200	01:03 L		< 2000	01:04 L		< 2000				
222																
227																
229																
232																
239																
242																
252																
267							01:03 L		< 2000							
268																
273																
277																
284																
293																
302																
303																
309																
351																
361	01:01 L		< 2000													

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	7	< 2000	2	< 2000	4	< 2000	3	< 2000	1	< 2000
	7	2000-5000	2	2000-5000	4	2000-5000	3	2000-5000	1	2000-5000
	0	> 5000	0	> 5000	0	> 5000	0	> 5000	0	> 5000
	0	0	0	0	0	0	0	0	0	0

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 310/2017

DESPATCHED ON 13TH JUNE 2017

DPB1* Antibodies - NOT ASSESSED

% reported

Lab no.
9
11
12
14
15
19
20
23
24
25
26
28
34
35
38
39
41
42
45
48
51
54
58
62
100
112
114
116
117
119
120
133
136
142
143
145
147
149
157
160
162
164
165
169
181
185
195
197
204
206
209
214
216
218
222
227
229
232
239
242
252
267
268
273
277
284
293
302
303
309
351
361

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = O

No. Reporting Spec

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 310/2017

DESPATCHED ON 13TH JUNE 2017

DPA1* Antibodies - NOT ASSESSED

% reported

Lab no.
9
11
12
14
15
19
20
23
24
25
26
28
34
35
38
39
41
42
45
48
51
54
58
62
100
112
114
116
117
119
120
133
136
142
143
145
147
149
157
160
162
164
165
169
181
185
195
197
204
206
209
214
216
218
222
227
229
232
239
242
252
267
268
273
277
284
293
302
303
309
351
361

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = C

No. Reporting Spec

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 310/2017

DESPATCHED ON 13TH JUNE 2017

Techniques used IgG	Sample Treatment IgG	High Background	Neg control serum batch	Allele Specific Antibodies		Luminex kit (lot)		Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot)		Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot)	Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative
				IgG	IgG	IgG	IgG										
Lab no.																	
9 L	EDTA	N				LS2A01	7400	30									
11 L	None	N	NC17			LSM12	2.5	5043	26								
12 L	EDTA	N	LOT 17			LS2A01	500	10309	29	LSM12	3	68	14250				
14 L	Heat/EDTA	N	17			LS2A01	1500	15008	38								
15 L	EDTA	N	17	Class II Negative		LS2A01	1000	12510	75								
19 L	EDTA	N				LS2A01	1000	9739	43								
20 L	EDTA	N				LS2A01	2000	10281	26								
23 L	EDTA	N	17			LS2A01	1000	11897	15.45								
24 L	None	N	017			LSM12	4.5	12282	47	LS2PRA	1000	11266	90				
25 L	EDTA	N	016			LS2A01	1000	11496	26	LSM12	6.1	9450	73				
26 L	EDTA	N	017														
28 L	None	N	17	DRB5*01:01		LS2A01	500	10471	26								
34 L	EDTA	N	016	DRB5*01:01		LS2A01	1136	10827	17								
35 L	EDTA	N				LS2A01	1000	13239	9								
38						LS2A01		14982	14	LS2PRA		16793	95				
39 L		N	LS-NC015			LS2A01	1300	11994	9								
41 L	None	N				LS2A01	2000	10496	26								
42 L	EDTA	N	017			LS2A01	500	8800	24								
45 L	Beads/EDTA	N				LS2A01	1500	10000	60								
48 L	Heat	N	17														
51 L		N				LS2A01	1600	13200	36								
54 L	EDTA	N	016			LS2A01	750	12241	57								
58 L	EDTA	N	016			LS2A01	1000	10740	38	LSM12	3	9389	41				
62 L	None	N				LS2A01	2000	10306	35.7								
100 L		N				LSAII	500	15519	194								
112 L	None	N	110B6D			LSAII	500	22591	385								
114 L	EDTA	N				LS2A01	1000	11418	13								
116 C/L	EDTA	N	17			LSM12		10872	37								
117 E/L	None	N	016			LS2A01	500	12074	16								
119	EDTA	N	016			LS2A01	>1000	15145	29	>1.5	13368	39					
120 L	EDTA	N				LS2A01	500	12087	11.67								
133 L	Heat	N	08256C	DQB1*05:01/05:03		LSAII	500	17283	832								
136 L	None	N				LS2A01	1000	12193	37								
142 L	EDTA	N				LS2A01	1000	13178	17								
143 L	None	N	017			LS2A01	1000	17020	28								
145																	
147 L	EDTA	N		DR1403 and DR1404 NT		LS2A01	>1500	25494	32	LSM12	>5	5762	11				
149 L	None	N				LSAII		15296	169								
157 L	EDTA	N	16			LS2A01	1000	18.46	15271								
160 L	Beads	N	LOT16			LS2A01	1000	10960	13.7								
162 L	EDTA	N				LSM12	3	10020	21								
164 L	EDTA	N				LS2A01	1500	12374	36								
165																	
169 L	None	N	IH			LS2A01	1000	6477	27								
181 L	None	N	16			LS2A01	500	12900	17								
185 L	EDTA	N		DQA1*01:03 DQB1*06:01		LSAII	2	17367	123	LM2	0	19183	74				
185 L	None	N				LS2A01	2000	11909	30								
197 L	None	N															
204 L	EDTA	N	LSNC			LS2A01	1000	12368	21								
206 L	EDTA	N				LS2A01	1000	12773	23								
209 L	Beads/EDTA	N				LS2A01		14736	166								
214																	
216 L	None	N	3005006	DQB1*05:02 DQB1*05:01 DQB1*05:01 DQB1*06:01 DQB1*06:04 DQA1*01:01 DQA1*01:02 DQA1*01:03 DQA1*01:04		LM2	1000	18334	475	LMX		14453					
L	Heat	N				LSAII		19310									
218																	
222 F	None																
227																	
229																	
232 L	None	N	NC17			LS2A01	1200	6205	31								
239 L	None	N				LM2	1100	19003	228								
242 L	Beads	N				LS2A01		18878	18								
252 L	None	N				LM2	2	15067	104								
267 L	EDTA	N				LSAII	700	12118	136								
268 C/L	None	N				LSAII	1500	15700	657	LM2	1000	18448	82				
273 L	None	N				LS2A01	1500	10295	25								
277 L	EDTA	N	016			LS2A01	500	8271	15								
284 L	EDTA	N				LS2A01	1000	12070	28								
293 L	None	N				LS2A01	500	8706	11.14	LS2PRA	500	8706	11.14				
302 L	None	N															
303 L	EDTA	N	017			LS2A01	1000	9726	46								
309 L	None	N				LSAII	500	17000	110								
351 L	EDTA	N	017			LS2A01	1500	14274	20								
361 L	None	N	3004913			LSAII	500	17074	187								

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other